Trial Information

An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study)

Subjects with metastatic colorectal cancer with KRAS-wildtype will be randomized in a 1:1
ratio to receive a 2nd line treatment regimen of panitumumab plus oxaliplatin and
capecitabine (XELOX) or XELOX alone. Before randomization tumour of all subjects will be
analyzed to detect the KRAS mutational status. Subjects will only be randomized into these
two arms if the tumour shows KRAS wild-type. Subjects with KRAS mutant colorectal tumours
will receive XELOX alone. Subjects will receive treatment cycles every three weeks.
Treatment will continue until subjects are diagnosed with disease progression or intolerable
toxicity, at which time the subjects will be withdrawn from the treatment phase. If a
subject withdraws from chemotherapy due to toxicity the subjects will be allowed to continue
with panitumumab monotherapy with or without one of the chemotherapy components until
disease progression. After withdrawing panitumumab and XELOX treatment, all subjects will
end the treatment phase and will enter a follow-up phase until 6 months after the last
patient stopped treatment (with a safety follow-up visit after 56 days ± 3 days and long
term follow-up visits every 12 weeks). During the treatment phase subjects will be evaluated
for tumour response every 9 weeks (± one week) through to week 45, and every 12 weeks (± two
weeks) thereafter, until disease progression. Subjects with symptoms suggestive of disease
progression should be evaluated for tumour response at the time symptoms occur.